

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01629K		APPLICATION NO.: 10/664,337	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Michael P. Dwyer et al.			
				FILING DATE: 09/17/2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 02/50079	06/27/2002	WIPO			
	AM	WO 97/16452	05/09/1997	WIPO			
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ	Nathanael Gray et al., "ATP-site Directed Inhibitors of Cyclin-dependent Kinases", <i>Current Medicinal Chemistry</i> , 6(9): 859-875, (1999).					
	AR	Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", <i>Journal of the National Cancer Institute</i> , 92(5): 376-387 (March 1, 2000).					
	AS						
	AT						
	AU						
	AV						
EXAMINER 				DATE CONSIDERED 3/12/06			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Sheet 1 of 1

PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

OC01629K

APPLICATION NO.:

10/664,337

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

Michael P. Dwyer *et al.*

FILING DATE:

09/17/2003

GROUP:

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	US 6,107,305	08/22/2000	Misra <i>et al.</i>			
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL	WO 01/35917	05/25/2001	PCT			
AM						
AN						
AO						
AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Vesely <i>et al.</i> , "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.
AR	Senderowicz <i>et al.</i> , "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
AS	Meijer <i>et al.</i> , "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243: 527-536.
AT	Bible <i>et al.</i> , "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.
AU	Shiota <i>et al.</i> , "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.
AV	Yasuo Makisumi <i>et al.</i> , "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines.", <i>Chem Pharm. Bull.</i> (1962), 10: 620-626.
AW	Aboul-Fadi <i>et al.</i> , "Effective and Variable Functionalization of Pyrazolo[1,5- α]pyridines Involving Palladium-Catalyzed Coupling Reactions", <i>Synthesis</i> 2000, (12): 1727-1732.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.